BFM
RPTX

Boothbay Fund Management’s Repare Therapeutics RPTX Stock Holding History

Boothbay Fund Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21,467
Closed -$661K – 1393
2020
Q3 		$661K Buy
+21,467
New +$568K 0.04% 565

Other funds holding RPTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boothbay Fund Management's RPTX Position: Q4 2020 in Review

Boothbay Fund Management sold out of Repare Therapeutics (RPTX) in Q4 2020, closing a stake of 21,467 shares — an estimated $661K sold.

Boothbay Fund Management first reported a position in RPTX in Q3 2020 and held it in 1 quarter. The position peaked at $661K in Q3 2020. 63 funds tracked by Wall St. Rank hold RPTX as of Q4 2020.

  • Boothbay Fund Management reported no remaining Repare Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 21,467 Repare Therapeutics shares in Q4 2020, an estimated $661K.
  • Boothbay Fund Management first reported a position in Repare Therapeutics in Q3 2020 and held it in 1 quarter.
  • Boothbay Fund Management's Repare Therapeutics position peaked at $661K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2020.

Based on Boothbay Fund Management's 13F filing for Q4 2020, filed 12 Feb 2021.